These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35675139)

  • 41. Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α-18F-fluoro-17β-estradiol PET/CT.
    van Kruchten M; de Vries EF; Arts HJ; Jager NM; Bongaerts AH; Glaudemans AW; Hollema H; de Vries EG; Hospers GA; Reyners AK
    J Nucl Med; 2015 Jan; 56(1):50-5. PubMed ID: 25476534
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnostic value of
    Tsuyoshi H; Tsujikawa T; Yamada S; Okazawa H; Yoshida Y
    Cancer Imaging; 2020 Oct; 20(1):75. PubMed ID: 33092631
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Additional value of 16α-[18F]fluoro-17β-oestradiol PET for differential diagnosis between uterine sarcoma and leiomyoma in patients with positive or equivocal findings on [18F]fluorodeoxyglucose PET.
    Yoshida Y; Kiyono Y; Tsujikawa T; Kurokawa T; Okazawa H; Kotsuji F
    Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1824-31. PubMed ID: 21656049
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma.
    van Kruchten M; Glaudemans AW; de Vries EF; Beets-Tan RG; Schröder CP; Dierckx RA; de Vries EG; Hospers GA
    J Nucl Med; 2012 Feb; 53(2):182-90. PubMed ID: 22241912
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer.
    Katzenellenbogen JA; Welch MJ; Dehdashti F
    Anticancer Res; 1997; 17(3B):1573-6. PubMed ID: 9179196
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Predictive Value of Early Changes in
    He M; Liu C; Shi Q; Sun Y; Zhang Y; Xu X; Yuan H; Zhang Y; Liu Y; Liu G; Di G; Yang Z; Wang Z; Shao Z
    Oncologist; 2020 Nov; 25(11):927-936. PubMed ID: 32272493
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 18F-FDG/18F-FES standardized uptake value ratio determined using PET predicts prognosis in uterine sarcoma.
    Yamamoto M; Tsujikawa T; Yamada S; Kurokawa T; Shinagawa A; Chino Y; Mori T; Kiyono Y; Okazawa H; Yoshida Y
    Oncotarget; 2017 Apr; 8(14):22581-22589. PubMed ID: 28186981
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular imaging of breast cancer.
    Oude Munnink TH; Nagengast WB; Brouwers AH; Schröder CP; Hospers GA; Lub-de Hooge MN; van der Wall E; van Diest PJ; de Vries EG
    Breast; 2009 Oct; 18 Suppl 3():S66-73. PubMed ID: 19914546
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Can
    Gupta M; Datta A; Choudhury PS; Dsouza M; Batra U; Mishra A
    World J Nucl Med; 2017; 16(2):133-139. PubMed ID: 28553180
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET.
    Kurland BF; Peterson LM; Lee JH; Linden HM; Schubert EK; Dunnwald LK; Link JM; Krohn KA; Mankoff DA
    J Nucl Med; 2011 Oct; 52(10):1541-9. PubMed ID: 21903739
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy.
    Dehdashti F; Flanagan FL; Mortimer JE; Katzenellenbogen JA; Welch MJ; Siegel BA
    Eur J Nucl Med; 1999 Jan; 26(1):51-6. PubMed ID: 9933662
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnostic value of PET/CT versus PET/MRI in gynecological malignancies of the pelvis: A meta-analysis.
    Virarkar M; Ganeshan D; Devine C; Bassett R; Kuchana V; Bhosale P
    Clin Imaging; 2020 Mar; 60(1):53-61. PubMed ID: 31864201
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Positron emission tomography for prostate, bladder, and renal cancer.
    Schöder H; Larson SM
    Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diagnostic performance of fluorodeoxyglucose positron emission tomography/magnetic resonance imaging fusion images of gynecological malignant tumors: comparison with positron emission tomography/computed tomography.
    Nakajo K; Tatsumi M; Inoue A; Isohashi K; Higuchi I; Kato H; Imaizumi M; Enomoto T; Shimosegawa E; Kimura T; Hatazawa J
    Jpn J Radiol; 2010 Feb; 28(2):95-100. PubMed ID: 20182843
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    Grabher BJ
    J Nucl Med Technol; 2023 Sep; 51(3):188-193. PubMed ID: 37433673
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 18F-Fluoroestradiol Tumor Uptake Is Influenced by Structural Components in Breast Cancer.
    Takahashi M; Maeda H; Tsujikawa T; Kono H; Mori T; Kiyono Y; Okazawa H; Noriki S; Imamura Y; Goi T
    Clin Nucl Med; 2021 Nov; 46(11):884-889. PubMed ID: 34319950
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gynecological cancers.
    Avril N; Gourtsoyianni S; Reznek R
    Methods Mol Biol; 2011; 727():171-89. PubMed ID: 21331934
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Systemic and cerebral kinetics of 16 alpha [18F]fluoro-17 beta-estradiol: a ligand for the in vivo assessment of estrogen receptor binding parameters.
    Moresco RM; Casati R; Lucignani G; Carpinelli A; Schmidt K; Todde S; Colombo F; Fazio F
    J Cereb Blood Flow Metab; 1995 Mar; 15(2):301-11. PubMed ID: 7860663
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [FDG-PET and endometrial cancer].
    Kolesnikov-Gauthier H; Carpentier P
    Bull Cancer; 2012 Jan; 99(1):21-8. PubMed ID: 22182739
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Distinctive FDG and FES accumulation pattern of two tamoxifen-treated patients with endometrial hyperplasia.
    Tsujikawa T; Okazawa H; Yoshida Y; Mori T; Kobayashi M; Tsuchida T; Fujibayashi Y
    Ann Nucl Med; 2008 Jan; 22(1):73-7. PubMed ID: 18250990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.